$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000162828017010727 Filed on November 02, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q3
Revenue	$2.534M	$6.892M	$774.0K
YoY Change	-1399.49%	790.44%	-80.96%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.540M	$3.660M	$3.720M
YoY Change	-25.16%	-1.61%	-51.75%
% of Gross Profit
Research & Development	$17.82M	$15.54M	$15.74M
YoY Change	3.85%	-1.28%	-3.77%
% of Gross Profit
Depreciation & Amortization	$620.0K	$593.0K	$291.0K
YoY Change	87.88%	103.78%	90.2%
% of Gross Profit
Operating Expenses	$21.99M	$19.79M	$19.75M
YoY Change	-1.04%	0.2%	-68.25%
Operating Profit	-$60.25M	-$12.90M	-$18.98M
YoY Change	-76.6%	-32.03%	-67.36%
Interest Expense	$210.0K	$76.00K	$0.00
YoY Change	-136.21%		-100.0%
% of Operating Profit
Other Income/Expense, Net		$1.297M	-$620.0K
YoY Change		-309.19%	-104.44%
Pretax Income	-$60.25M	-$11.60M	-$19.60M
YoY Change	-76.72%	-40.8%	-55.65%
Income Tax	-$7.420M	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$35.93M	-$11.60M	-$19.60M
YoY Change	-83.57%	-40.8%	-32.39%
Net Earnings / Revenue	-1417.96%	-168.31%	-2531.65%
Basic Earnings Per Share
Diluted Earnings Per Share	-$652.6K	-$211.4K	-$365.3K
COMMON SHARES
Basic Shares Outstanding	55.05M shares	55.03M shares	54.80M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$126.4M	$88.20M	$149.7M
YoY Change	-3.22%	-41.08%	-23.66%
Cash & Equivalents	$54.29M	$15.23M	$26.63M
Short-Term Investments	$72.10M	$73.00M	$123.1M
Other Short-Term Assets	$2.100M	$1.500M	$1.500M
YoY Change	61.54%	0.0%	25.0%
Inventory
Prepaid Expenses
Receivables	$402.0K	$846.0K	$395.0K
Other Receivables	$400.0K	$100.0K	$200.0K
Total Short-Term Assets	$129.4M	$90.81M	$151.8M
YoY Change	-2.41%	-40.18%	-24.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.18M	$12.62M	$4.086M
YoY Change	75.42%	208.91%	77.65%
Goodwill	$24.36M	$24.36M	$162.5M
YoY Change	0.0%	-85.01%
Intangibles	$58.65M	$99.45M	$196.3M
YoY Change	-41.03%	-49.34%
Long-Term Investments	$0.00		$0.00
YoY Change			-100.0%
Other Assets	$12.60M	$12.60M
YoY Change	0.0%
Total Long-Term Assets	$107.8M	$149.0M	$362.9M
YoY Change	-24.81%	-58.94%	-30.56%
TOTAL ASSETS
Total Short-Term Assets	$129.4M	$90.81M	$151.8M
Total Long-Term Assets	$107.8M	$149.0M	$362.9M
Total Assets	$237.2M	$239.8M	$514.7M
YoY Change	-14.05%	-53.4%	-28.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.000M	$2.300M	$2.100M
YoY Change	-37.5%	9.52%	-27.59%
Accrued Expenses	$8.600M	$4.100M	$4.800M
YoY Change	36.51%	-14.58%	11.63%
Deferred Revenue	$2.742M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.63M	$8.235M	$8.392M
YoY Change	38.19%	-1.87%	-39.19%
LONG-TERM LIABILITIES
Long-Term Debt	$12.00M	$12.00M	$0.00
YoY Change	0.0%
Other Long-Term Liabilities	$11.10M	$11.00M	$8.300M
YoY Change	21.98%	32.53%	-38.97%
Total Long-Term Liabilities	$23.10M	$23.00M	$8.300M
YoY Change	9.48%	177.11%	-38.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.63M	$8.235M	$8.392M
Total Long-Term Liabilities	$23.10M	$23.00M	$8.300M
Total Liabilities	$54.69M	$72.45M	$98.11M
YoY Change	-25.0%	-26.15%	-41.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$738.1M	-$699.6M	-$432.5M
YoY Change	13.07%	61.78%
Common Stock	$876.1M	$876.0M	$864.4M
YoY Change	1.0%	1.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$182.5M	$167.4M	$416.6M
YoY Change
Total Liabilities & Shareholders Equity	$237.2M	$239.8M	$514.7M
YoY Change	-14.05%	-53.4%	-28.77%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$35.93M	-$11.60M	-$19.60M
YoY Change	-83.57%	-40.8%	-32.39%
Depreciation, Depletion And Amortization	$620.0K	$593.0K	$291.0K
YoY Change	87.88%	103.78%	90.2%
Cash From Operating Activities	-$10.34M	-$15.68M	-$14.71M
YoY Change	-30.28%	6.58%	482.19%
INVESTING ACTIVITIES
Capital Expenditures	-$180.0K	$538.0K	$168.0K
YoY Change	-93.08%	220.24%	-71.48%
Acquisitions
YoY Change
Other Investing Activities	$900.0K	$5.840M	-$710.0K
YoY Change	-72.97%	-922.54%	-95.86%
Cash From Investing Activities	$710.0K	$5.305M	-$880.0K
YoY Change	-2.74%	-702.84%	-95.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	48.90M	$61.00K	$76.00K
YoY Change	307.5%	-19.74%	-34.48%
NET CHANGE
Cash From Operating Activities	-10.34M	-$15.68M	-$14.71M
Cash From Investing Activities	710.0K	$5.305M	-$880.0K
Cash From Financing Activities	48.90M	$61.00K	$76.00K
Net Change In Cash	39.27M	-$8.987M	-$15.52M
YoY Change	-1970.0%	-42.08%	-22.97%
FREE CASH FLOW
Cash From Operating Activities	-$10.34M	-$15.68M	-$14.71M
Capital Expenditures	-$180.0K	$538.0K	$168.0K
Free Cash Flow	-$10.16M	-$16.22M	-$14.88M
YoY Change	-16.93%	8.99%	377.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	2178000	USD
CY2017Q3	abus	Accrued Payroll Current AccruedPayrollCurrent	189000	USD
	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	2966000	USD
	abus	Royalty Guarantees Commitments Percentage RoyaltyGuaranteesCommitmentsPercentage	0.025
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-133000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3867000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-49782000	USD
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-49782000	USD
CY2016Q4	abus	Accrued Research And Development AccruedResearchAndDevelopment	3131000	USD
CY2017Q3	abus	Accrued Research And Development AccruedResearchAndDevelopment	2955000	USD
	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	-962000	USD
CY2017Q1	abus	Classof Warrantor Rights Expired ClassofWarrantorRightsExpired	22000	shares
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	36543000	USD
CY2017Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	40755000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13170000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4978101	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5339714	shares
	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	3702000	CAD
CY2016Q4	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	553000	USD
CY2017Q3	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	1817000	USD
CY2016Q4	abus	Employee Stock Options Liability Classified Outstanding Fair Value Disclosure EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure	553000	USD
CY2017Q3	abus	Employee Stock Options Liability Classified Outstanding Fair Value Disclosure EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure	1817000	USD
	abus	Fair Value Of Warrants Exercised In The Period FairValueOfWarrantsExercisedInThePeriod	247000	USD
	abus	Fair Value Of Warrants Exercised In The Period FairValueOfWarrantsExercisedInThePeriod	129000	USD
CY2016Q3	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	260000	USD
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	756000	USD
CY2017Q3	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	197000	USD
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	1146000	USD
	abus	Increase Decrease In Value Of Warrants IncreaseDecreaseInValueOfWarrants	-339000	USD
	abus	Increase Decrease In Value Of Warrants IncreaseDecreaseInValueOfWarrants	22000	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	9323000	CAD
	abus	Maximum Contribution For Product MaximumContributionForProduct	7179000	USD
CY2006Q2	abus	Number Of Chemotherapy Products With Worldwide Licenses NumberOfChemotherapyProductsWithWorldwideLicenses	3	chemotherapy_products
CY2016Q3	abus	Option Exercised Contractual Option Revenue Amount OptionExercisedContractualOptionRevenueAmount	0	USD
	abus	Option Exercised Contractual Option Revenue Amount OptionExercisedContractualOptionRevenueAmount	1000000	USD
CY2017Q3	abus	Option Exercised Contractual Option Revenue Amount OptionExercisedContractualOptionRevenueAmount	0	USD
	abus	Option Exercised Contractual Option Revenue Amount OptionExercisedContractualOptionRevenueAmount	0	USD
	abus	Percent Of Costs Funded By Tpc PercentOfCostsFundedByTPC	0.27
CY2017Q3	abus	Wholly Owned Subsidiaries Includedin Financial Statements WhollyOwnedSubsidiariesIncludedinFinancialStatements	2	subsidiary
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55051995	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Arbutus Biopharma Corp
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9910000	USD
CY2017Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6403000	USD
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3215000	USD
CY2017Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2291000	USD
CY2016Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	273000	USD
CY2017Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	846000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	273000	USD
CY2017Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	846000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	498000	USD
CY2017Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	226000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10738000	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12125000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24212000	USD
CY2017Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	197000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1146000	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	143160000	USD
CY2016Q4	us-gaap	Assets Assets	275919000	USD
CY2017Q3	us-gaap	Assets Assets	239845000	USD
CY2015Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7497000	USD
CY2016Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	8253000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	132564000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	90813000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	9065000	USD
CY2017Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10211000	USD
CY2016Q3	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	266000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	266000	USD
CY2017Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	100780000	USD
CY2016Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	260000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	756000	USD
CY2017Q3	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	-6000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166779000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42970000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26630000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23413000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15225000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	23413000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	15225000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-16340000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-140149000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8987000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8188000	USD
CY2016Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2017Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54841494	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55051983	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54841494	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55051983	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	867393000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	876049000	USD
CY2016Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-64864000	USD
CY2017Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2017Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	744000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	15000	USD
CY2017Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	15000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	41263000	USD
CY2017Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	41263000	USD
CY2016Q3	us-gaap	Depreciation Depreciation	291000	USD
	us-gaap	Depreciation Depreciation	760000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2458000	USD
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	339000	USD
CY2017Q3	us-gaap	Depreciation Depreciation	593000	USD
	us-gaap	Depreciation Depreciation	1407000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.15
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.89
CY2016Q3	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-824000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2131000	USD
CY2017Q3	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	1327000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2575000	USD
CY2016Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	10000	USD
CY2017Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	USD
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-22000	USD
CY2016Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-795000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2180000	USD
CY2017Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1233000	USD
CY2016Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-826000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	2130000	USD
CY2017Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1328000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	2578000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3720000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34705000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3659000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12586000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	24364000	USD
CY2017Q3	us-gaap	Goodwill Goodwill	24364000	USD
CY2016Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	156324000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2016Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	156324000	USD
CY2017Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-19595000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-230333000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-11600000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-48482000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-64864000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	293000	USD
CY2017Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	160000	USD
CY2016Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-887000	USD
CY2016Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-61000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-613000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1961000	USD
CY2017Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-196000	USD
CY2017Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-6739000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2016Q3	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-98000	USD
CY2017Q3	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	573000	USD
CY2016Q3	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
CY2017Q3	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-744000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-744000	USD
CY2016Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-696000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1066000	USD
CY2017Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1805000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3513000	USD
CY2016Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-584000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	263000	USD
CY2017Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-83000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	189000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	99445000	USD
CY2017Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	99445000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	0	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	76000	USD
	us-gaap	Interest Expense InterestExpense	186000	USD
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	425000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1104000	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	337000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1095000	USD
CY2016Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	107146000	USD
CY2017Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	72954000	USD
CY2016Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	350000	USD
CY2017Q3	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	38000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	72914000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	72454000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	275919000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	239845000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10585000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8235000	USD
CY2016Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	9725000	USD
CY2017Q3	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	12028000	USD
CY2016Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	12001000	USD
CY2017Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	12001000	USD
CY2016Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	76000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	637000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	61000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	419000	USD
CY2016Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-880000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-99854000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5305000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	27116000	USD
CY2016Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14712000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-43063000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15680000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38298000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-19595000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-165469000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-11600000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-48482000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-620000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1297000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2199000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	19749000	USD
	us-gaap	Operating Expenses OperatingExpenses	235886000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	19789000	USD
	us-gaap	Operating Expenses OperatingExpenses	58847000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18975000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-234200000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12897000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-50681000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	538000	USD
CY2017Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	704000	USD
CY2016Q3	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	712000	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	98457000	USD
CY2017Q3	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-5843000	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-34192000	USD
CY2016Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	168000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1397000	USD
CY2017Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	538000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7076000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1311000	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1500000	USD
CY2016Q3	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	0	USD
	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	0	USD
CY2017Q3	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	108000	USD
	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	108000	USD
CY2016Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	76000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	192000	USD
CY2017Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	61000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	66000	USD
CY2016Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	445000	USD
CY2017Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	353000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17683000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24747000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6945000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12622000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15738000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44097000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15537000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44854000	USD
CY2016Q4	us-gaap	Restricted Investments At Fair Value RestrictedInvestmentsAtFairValue	12601000	USD
CY2017Q3	us-gaap	Restricted Investments At Fair Value RestrictedInvestmentsAtFairValue	12601000	USD
CY2016Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	12601000	USD
CY2017Q3	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	12601000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-651149000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-699631000	USD
CY2016Q3	us-gaap	Revenues Revenues	774000	USD
	us-gaap	Revenues Revenues	1686000	USD
CY2017Q3	us-gaap	Revenues Revenues	6892000	USD
	us-gaap	Revenues Revenues	8166000	USD
CY2017Q3	us-gaap	Share Price SharePrice	6.20
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	107146000	USD
CY2017Q3	us-gaap	Short Term Investments ShortTermInvestments	72954000	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	481000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	179000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	203005000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	167391000	USD
CY2016Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	128000	USD
CY2017Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	128000	USD
CY2016Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	107000	USD
CY2017Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2015Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	883000	USD
CY2016Q3	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	297000	USD
CY2016Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	107000	USD
CY2017Q3	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	0	USD
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53652007	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52588505	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54877103	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54612081	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of business and future operations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (the “Company” or “Arbutus”) is a biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (“HBV”). The Company's portfolio of assets includes a broad pipeline of drug candidates to develop a cure for HBV and leverages the Company’s expertise in Lipid Nanoparticle ("LNP") technology.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The continuation of the research and development activities and the commercialization of its products are dependent on the Company’s ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of future research and development programs or the Company’s ability to continue to fund these programs in the future.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-17-010727-index-headers.html	Edgar Link	pending
0001628280-17-010727-index.html	Edgar Link	pending
0001628280-17-010727.txt	Edgar Link	pending
0001628280-17-010727-xbrl.zip	Edgar Link	pending
abus-20170930.xml	Edgar Link	completed
abus-20170930.xsd	Edgar Link	pending
abus-20170930_cal.xml	Edgar Link	unprocessable
abus-20170930_def.xml	Edgar Link	unprocessable
abus-20170930_lab.xml	Edgar Link	unprocessable
abus-20170930_pre.xml	Edgar Link	unprocessable
arbutusq32017.htm	Edgar Link	pending
exhibit101q32017.htm	Edgar Link	pending
exhibit311q32017.htm	Edgar Link	pending
exhibit312q32017.htm	Edgar Link	pending
exhibit321q32017.htm	Edgar Link	pending
exhibit322q32017.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pipeline2017a01.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2017 Q4 Form 10-Q Financial Statement

#000162828017010727 Filed on November 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2017 Q4 Form 10-Q Financial Statement

#000162828017010727 Filed on November 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus